Sherif Ragab
Psychiatry · Merriam, KSNPI 1336308220
Payments from drug & device makers
Across 19 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$65
- Otsuka America Pharmaceutical, Inc.$58
- AbbVie$54
- Noven Therapeutics, LLC$37
- Alkermes, Inc.$29
- Johnson & Johnson$25
- plus $134 from 7 others
What the payments were for
- Food & beverage$401100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| AbbVie | 3 | $54 |
| Noven Therapeutics, LLC | 2 | $37 |
| Alkermes, Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Corium, LLC | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$401 in reported general payments places this provider in the 60th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 156 | $3,520 |
| Aripiprazole | 44 | $3,150 |
| Chlorpromazine Hcl | 13 | $2,717 |
| Duloxetine Hcl | 117 | $2,118 |
| Quetiapine Fumarate | 120 | $2,089 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 102 | $1,854 |
| Olanzapine | 49 | $1,372 |
| Hydroxyzine Hcl | 40 | $1,316 |
| Trazodone Hcl | 146 | $1,212 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 41 | $1,182 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $1,180 |
| Atomoxetine Hcl | 15 | $1,145 |
| Doxepin Hcl | 35 | $1,034 |
| Mirtazapine | 64 | $943 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $854 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Merriam
- Debra KelshKansas City$25.2M
- Paul MurphyWichita$3.9M
- Matthew ByerlyWichita$792K
- David WichmanManhattan$613K
- Kevin MaysLeawood$558K
- Sheldon PreskornWichita$498K
- James OwensSalina$433K
- Tyler KjorvestadKansas City$124K
- Sasha HamdaniOverland Park$104K
- William JohnsonJunction City$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.